News
MEDP
571.02
+1.67%
9.37
INBS Stock Surges 132.4% on New Manufacturing Partnership
NASDAQ · 2d ago
Here's Why You Should Add Inogen Stock to Your Portfolio Now
NASDAQ · 2d ago
1 Unpopular Stock That Deserves Some Love and 2 We Find Risky
Barchart · 4d ago
Why Medpace (MEDP) Dipped More Than Broader Market Today
NASDAQ · 12/31/2025 23:15
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
NASDAQ · 12/31/2025 15:52
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform
NASDAQ · 12/31/2025 15:49
ESTA Shares Dip Despite FDA Filing for Motiva Breast Reconstruction
NASDAQ · 12/30/2025 17:45
Weekly Report: what happened at MEDP last week (1222-1226)?
Weekly Report · 12/29/2025 09:42
Medpace (MEDP): Assessing Valuation After a Strong Multi‑Year Share Price Run
Simply Wall St · 12/24/2025 22:56
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
NASDAQ · 12/24/2025 17:29
BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens
NASDAQ · 12/23/2025 17:07
Adaptive Biotechnologies is the top performing life sciences tools and services stock YTD
Seeking Alpha · 12/23/2025 05:06
Here's Why You Should Retain INSP Stock in Your Portfolio Now
NASDAQ · 12/22/2025 12:51
Weekly Report: what happened at MEDP last week (1215-1219)?
Weekly Report · 12/22/2025 09:41
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
NASDAQ · 12/19/2025 23:15
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
NASDAQ · 12/19/2025 15:25
Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica
NASDAQ · 12/19/2025 13:41
ECL Boosts High-Tech Water Platform With Ovivo's Electronics Business
NASDAQ · 12/18/2025 16:00
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
NASDAQ · 12/18/2025 14:07
Here's Why You Should Retain CLOV Stock in Your Portfolio Now
NASDAQ · 12/18/2025 13:28
More
Webull provides a variety of real-time MEDP stock news. You can receive the latest news about Medpace Holdings through multiple platforms. This information may help you make smarter investment decisions.
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.